Completed Access to Information Requests

Follow:

  • RSS
  • Cite
About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 62170 record(s)

Req # A-2023-000916

The Abbreviated New Drug Submission (ANDS) no. 262177 filed by JAMP Pharma Corporation for nintedanib or nintedanib esilate, copies of any Notice of Deficiency (NOD), Notice of Non-Compliance (NON), NOD-Withdrawal (NOD-W), or NON-Withdrawal (NON-W), and any correspondence from or to JAMP Pharma regarding withdrawal or cancellation of the 100 mg strength of its nintedanib product from the ANDS.

Organization: Health Canada

16 page(s)
January 2024

Req # A-2023-000918

Abbreviated New Drug Submission (ANDS) no. 262177 filed by JAMP for nintedanib or nintedanib esilate, copies of any response by JAMP to any Notice of Deficiency (NOD), Notice of Non-Compliance (NON), NOD-Withdrawal (NOD-W), or NON-Withdrawal (NON-W).

Organization: Health Canada

34 page(s)
January 2024

Req # A-2023-000968

Information on the intended use of a device listed on Medical Device Active License Listing (MDALL). Requesting it for the following: Licence No.: 95942, Type: System, Device class: 2, Device first issue date 2015-10-15, Licence name: VIASURE, Device first issue date: 2015-10-15, Device name: OW100 - APPLICATORS, Identifier first issue date: 2015-10-15, Device identifiers: OE035, OE050, OP155 and Device first issue date: 2021-08-05, Device name - VIASURE, Identifier first issue date: 2021-08-05, Device identifiers: 1000017.

Organization: Health Canada

4 page(s)
January 2024

Req # A-2023-000970

Briefing notes, emails, meeting appointments, or minutes involving, addressed to or received by the Minister or the Deputy Minister at Health Canada and their Offices from the Public Health Agency of Canada, and correspondence sent or addressed to the Minister or the Deputy Minister at Health Canada and their Offices from sources external to Health Canada and the Public Health Agency of Canada regarding the broader phenomenon of cases involving or patients enduring atypical neurological diseases in New Brunswick for the period May 01, 2023 to October 18, 2023.

Organization: Health Canada

8 page(s)
January 2024

Req # A-2023-001022

The Certified Product Information Document (CPID) submitted for the Liraglutide Abbreviated New Drug Submission (ANDS).

Organization: Health Canada

28 page(s)
January 2024

Req # A-2023-001023

The Abbreviated New Drug Submission (ANDS) cover letter of the company who submitted the Liraglutide ANDS.

Organization: Health Canada

9 page(s)
January 2024

Req # A-2023-001025

Any Screening Acceptance Letter sent by Health Canada to the sponsor of the Liraglutide Abbreviated New Drug Submission (ANDS).

Organization: Health Canada

2 page(s)
January 2024

Req # A-2023-001171

Information about whether or not Canada donates or sends blood to foreign countries and if yes to which countries did Canada send blood during the years from 2019 until present time.

Organization: Health Canada

0 page(s)
January 2024

Req # A-2023-001214

Correspondence relating to any abbreviated new drug submission (ANDS) filed since July 1, 2023 where the medicinal ingredient is liraglutide alone and the indication includes chronic weight management.

Organization: Health Canada

0 page(s)
January 2024

Req # A-2023-001223

Complete copy of documents in your possession relating to the subject company. NEQ : 1167802090.

Organization: Health Canada

0 page(s)
January 2024
Date modified: